High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation

Blood

Volumn 118, Issue 13, 2011, Pages 3504-3511

  Gökbuget, Nicola ^a   Basara, Nadezda ^b,r   Baurmann, Herrad ^c   Beck, Joachim ^d   Brüggemann, Monika ^e   Diedrich, Helmut ^f   Güldenzoph, Björn ^g   Hartung, Gernot ^h   Horst, Heinz August ^e   Hüttmann, Andreas ⁱ   Kobbe, Guido ^j   Naumann, Ralph ^k,q   Ratei, Richard ^l   Reichle, Albrecht ^m   Serve, Hubert ^a   Stelljes, Matthias ⁿ   Viardot, Andreas ^o   Wattad, Mohammed ^p   Hoelzer, Dieter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h KLINIKUM OLDENBURG   (Germany)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^k DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^l HELIOS KLINIKUM BERLIN BUCH   (Germany)

^m UNIVERSITY HOSPITAL REGENSBURG   (Germany)

ⁿ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^o UNIVERSITY HOSPITAL ULM   (Germany)

^p Eye Hospital   (Germany)

^q Stiftungsklinikum Mittelrhein   (Germany)

^r St Franziskus Hospital   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUSULFAN; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; NELARABINE; TREOSULFAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALERTNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLAST CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; COGNITIVE DEFECT; CONFUSION; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENGRAFTMENT; ERYTHROCYTE; FATIGUE; FEMALE; GRAFT VERSUS HOST REACTION; GRANULOCYTOPENIA; HALLUCINATION; HUMAN; INSOMNIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; QUADRIPLEGIA; RESTLESSNESS; SIDE EFFECT; SOMNOLENCE; STEM CELL TRANSPLANTATION; THROMBOCYTE; THROMBOCYTOPENIA; TREMOR; WHOLE BODY RADIATION;

EID: 80053345056     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-329441     Document Type: Article

References (23)

1. Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009; 46(1):64-75.
2. Hoelzer D, Thiel E, Arnold R, et al. Successful subtype oriented treatment strategies in adult T-ALL: results of 744 patients treated in three consecutive GMALL studies [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(21): 324.
3. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009; 114(25):5136-5145.
4. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944-950. (Pubitemid 46220637)
5. Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21(9):1907-1914. (Pubitemid 47299963)
6. Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95(4):589-596.
7. Lambe CU, Averett DR, Paff MT, Reardon JE, Wilson JG, Krenitsky AT. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995;55(15):3352-3356.
8. Cohen A, Lee JW, Gelfand EW. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood. 1983;61(4):660-666. (Pubitemid 13115364)
9. Verhoef V, Fridland A. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res. 1985;45(8):3646-3650. (Pubitemid 15226439)
10. Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005;23(15):3396-3403.
11. Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005;23(15):3376-3382.
12. DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109(12):5136-5142. (Pubitemid 46890527)
13. Baldus CD, Martus P, Burmeister T, et al. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol. 2007;25(24):3739-3745. (Pubitemid 47376607)
14. van der Velden V, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/ TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604-611. (Pubitemid 46444541)
15. Berg SL, Brueckner C, Nuchtern JG, Dauser R, McGuffey L, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. Cancer Chemother Pharmacol. 2007;59(6):743-747. (Pubitemid 46440596)
16. Raetz EA, Perkins SL, Bhojwani D, et al. Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer. 2006;47(2):130-140. (Pubitemid 44025244)
17. Uyttebroeck A, vanhentenrijk V, Hagemeijer A, et al. Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma? Leuk Lymphoma. 2007;48(9):1745-1754. (Pubitemid 47386710)
18. O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113(11): 3186-3191.
19. Bader P, Kreyenberg H, Henze GH, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2009;27(3):377-384.
20. Knechtli CF, Goulden NJ, Hancok JP, et al. Minimal residual disease statues before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood. 1998;92(11):4072-4079. (Pubitemid 28544322)
21. Papayannidis C, Iacobucci I, Abbenante MC, et al. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. Am J Hematol. 2010;85(8):608.
22. Gandhi V, Plunkett W, Rodriguez C, et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol. 1998;16(11):3607-3615. (Pubitemid 28506775)
23. Cooper TM. Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manag. 2007;3(6):1135-1141.